Literature DB >> 8395169

Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart.

V J Dzau1.   

Abstract

While the circulating renin-angiotensin system (RAS) plays an important role in short-term maintenance of cardiovascular homeostasis, recent studies point to a role in long-term cardiovascular regulation for endogenous RAS in target tissues. This article focuses on the multiple effects of tissue angiotensin enzyme (ACE) and angiotensin II (Ang II), its active peptide product. Ang II has been shown to be a potent growth factor in vascular smooth muscle cells. Depending on the local conditions, the vascular response may be either hypertrophy or hyperplasia. The molecular mechanisms involved in the interactions of Ang II with endothelium- and smooth muscle-derived cell products may play important roles in the modulation of vascular structure in hypertension and vascular injury. Evidence also points to a role for Ang II in the development of left ventricular hypertrophy in hypertension. In addition, cardiac RAS may contribute to the pathophysiology of heart failure. Experimental and clinical studies with ACE inhibitors point to a role for tissue ACE activity in the development of atherosclerosis, as well as cardiac hypertrophy and remodeling.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395169     DOI: 10.1007/978-3-642-72497-8_1

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  15 in total

1.  Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion.

Authors:  Tadashi Suehiro; Tatsuhito Morita; Mari Inoue; Yoshitaka Kumon; Yukio Ikeda; Kozo Hashimoto
Journal:  Hum Genet       Date:  2004-05-26       Impact factor: 4.132

Review 2.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 3.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

4.  Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. No relation between the polymorphism and aortic collagen content.

Authors:  L M Rasmussen; T Ledet
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

5.  Angiotensin II reduces infarct size and has no effect on post-ischaemic contractile dysfunction in isolated rat hearts.

Authors:  W R Ford; A S Clanachan; C R Hiley; B I Jugdutt
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent.

Authors:  Komal Sodhi; Cheng-Chia Wu; Jennifer Cheng; Katherine Gotlinger; Kazuyoshi Inoue; Mohan Goli; John R Falck; Nader G Abraham; Michal L Schwartzman
Journal:  Hypertension       Date:  2010-09-13       Impact factor: 10.190

7.  Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits.

Authors:  H Mitani; T Bandoh; J Ishikawa; M Kimura; T Totsuka; S Hayashi
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

8.  Expression of local renin and angiotensinogen mRNA in cirrhotic portal hypertensive patient.

Authors:  Li Zhang; Zhen Yang; Bao-Min Shi; Da-Peng Li; Chong-Yun Fang; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 9.  Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure.

Authors:  Irving H Zucker; Harold D Schultz; Kaushik P Patel; Wei Wang; Lie Gao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

10.  Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.

Authors:  Nikolaos Tzemos; Pitt O Lim; Thomas M MacDonald
Journal:  Cardiovasc Ther       Date:  2009-07-14       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.